Latest Global Growth News

Servcorp Limited has upgraded its FY2026 profit and cash flow guidance, reflecting robust operational momentum and improved revenue efficiency across its global serviced office portfolio.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

RocketBoots Limited has slightly increased its recent capital raising, issuing an additional 100,000 shares to raise a total of A$7.025 million, reinforcing its push into international markets.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

WAM Active Limited has reported its strongest investment performance since inception, with a 41.4% return over 12 months and increased fully franked dividends, signalling confidence in its dynamic portfolio strategy heading into 2026.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Metallium Limited has initiated commissioning at its Texas Technology Campus following a successful first chlorine flash using its proprietary Flash Joule Heating technology, marking a significant step toward commercial operations.

RocketBoots Limited has successfully raised A$7 million through a placement to accelerate its international expansion following a transformative global contract. The capital injection aims to scale its AI-driven loss-prevention platform and convert a robust enterprise pipeline.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

Memphasys has inked a five-year supply agreement with Italy’s Centro Fertilita Assistita, marking its first major European contract and setting the stage for broader adoption of its Felix™ sperm isolation system.

RemSense Technologies has secured a follow-up contract with ExxonMobil to deliver advanced digital twin solutions at the Bass Strait facility, reinforcing its role in the energy sector’s digital transformation.